It is a muscarinic M1 positive allosteric modulator (M1-PAM) designed to improve cognition in disorders like Alzheimer's and schizophrenia.

What did the Phase 1 study show?

It enrolled 64 healthy volunteers, showed no dose-limiting toxicities, serious adverse events, or discontinuations, and demonstrated projected therapeutic exposures with a 7-11 hour half-life.

How does this compare to Suven's other pipeline assets?

SUVN-I6107 is the fifth internally discovered NCE, but it is earlier stage than Masupirdine (Phase 3 for Alzheimer's) and Samelisant (Phase 2/3 for narcolepsy).

What are the next steps?

Suven plans to advance SUVN-I6107 into Phase 2 clinical development, though no specific timeline was provided.

Does this change Suven's near-term financial outlook?

No. The company reported ₹2 cr in sales and a ₹46 cr net loss in Mar 2026. Phase 1 data do not generate revenue or alter the loss trajectory.

Earnings · Pharmaceuticals · Mid cap

Suven's experimental cognitive drug clears Phase 1 safety hurdle

SUVN-I6107, Suven's fifth internally discovered neuroscience NCE, showed no serious adverse events in 64 healthy volunteers and is moving into Phase 2.

— 3 earlier stories on Suven Life Sciences Ltd. →

SUVEN By Tipsheet Editorial 16 Jun 2026 · 9:27 AM IST Verify on BSE · NSE

Mkt cap₹6,919 cr

ROE0.00%

Debt / eq.0.00

64 volunteers Phase 1 study enrollment – no dose-limiting toxicities or discontinuations

What's new

Positive Phase 1 data for SUVN-I6107, a muscarinic M1 PAM for cognitive disorders.
No serious adverse events, dose-limiting toxicities, or treatment discontinuations.
Suven is advancing the compound into Phase 2 development.

Why this matters

For a clinical-stage biopharma with negligible revenue (₹2 cr in Mar 2026) and net losses, each pipeline milestone counts. This fifth NCE is incremental; the real catalysts remain later-stage Masupirdine (Phase 3) and Samelisant (Phase 2/3).

What we're watching

Phase 2 trial design and recruitment timeline for SUVN-I6107.
Masupirdine Phase 3 enrollment progress (88% target enrolled as of June 2026).
Samelisant Phase 2/3 data readout from SLEEP-2026.

The full read

Suven Life Sciences has another candidate in the pipeline. For now, that's what matters. The company reported positive Phase 1 data for SUVN-I6107, its fifth internally discovered neuroscience NCE, in 64 healthy volunteers. No safety issues emerged, and PK data hit therapeutic exposures with a 7 to 11 hour half-life. CNS activity was confirmed via biomarkers. But Phase 1 is the easy part. Suven already runs Phase 3 for Masupirdine and Phase 2/3 for Samelisant. For a company with ₹2 cr in quarterly revenue and a ₹46 cr net loss, this news adds pipeline depth, not near-term revenue. The stock's next tests remain the later-stage readouts, not this early win.

Questions answered

What is SUVN-I6107?: It is a muscarinic M1 positive allosteric modulator (M1-PAM) designed to improve cognition in disorders like Alzheimer's and schizophrenia.
What did the Phase 1 study show?: It enrolled 64 healthy volunteers, showed no dose-limiting toxicities, serious adverse events, or discontinuations, and demonstrated projected therapeutic exposures with a 7-11 hour half-life.
How does this compare to Suven's other pipeline assets?: SUVN-I6107 is the fifth internally discovered NCE, but it is earlier stage than Masupirdine (Phase 3 for Alzheimer's) and Samelisant (Phase 2/3 for narcolepsy).
What are the next steps?: Suven plans to advance SUVN-I6107 into Phase 2 clinical development, though no specific timeline was provided.
Does this change Suven's near-term financial outlook?: No. The company reported ₹2 cr in sales and a ₹46 cr net loss in Mar 2026. Phase 1 data do not generate revenue or alter the loss trajectory.

Mentioned: SUVN-I6107 · 64 volunteers · Phase 2

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Suven Life Sciences Ltd.

Pharmaceuticals

₹7,127 cr

Latest quarter · Mar 2026

Sales₹2 cr

Net profit−₹46 cr

Op. margin−3331.1%

EPS−₹1.73

Strength & growth

Debt / equity0.00×

Current ratio3.21×

Sales CAGR−34.6%

Story so far

All notes on SUVEN →

16 Jun 2026 · 9:27 AM IST Suven's experimental cognitive drug clears Phase 1 safety hurdle
today Suven's Ropanicant clears Phase 2b, cuts depression scores 3.6 points vs placebo
5d ago Suven to show Samelisant Phase 2 data at SLEEP-2026
13d ago Suven's Alzheimer's drug passes a critical Phase 3 safety check.